Pricing Log in Create free account

GH Research PLC (GHRS) vs Urogen Pharma (URGN)

GH Research PLC and Urogen Pharma are both Biotechnology companies. GH Research PLC and Urogen Pharma are of similar size ($1.3B and $1.3B). GH Research PLC has the higher net margin (0.00% vs −26.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, GH Research PLC leads on 7 and Urogen Pharma on 5.

Valuation

Metric GHRS URGN Biotechnology median
P/E n/m n/m 10.60
P/S n/m 5.01 9.40
P/B 3.42 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 5.41 9.02
Earnings yield (5.41%) (5.32%) (32.88%)
Free cash flow yield (4.21%) (10.53%) (23.13%)

Profitability

Metric GHRS URGN Biotechnology median
Gross margin 0.00% 91.41% 68.51%
Operating margin 0.00% (12.36%) 0.00%
Net margin 0.00% (26.27%) 0.00%
Free cash flow margin 0.00% (52.77%) 0.00%
Return on equity (18.79%) 54.65% (51.96%)
Return on assets (18.16%) (28.78%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GHRS URGN Biotechnology median
Revenue growth (TTM) — 159.29% 6.76%
EPS growth (last fiscal year) (5.33%) (7.77%) 29.88%
Revenue growth, 5-year CAGR — 56.22% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GHRS URGN Biotechnology median
Debt to equity 0.00 (1.53) 0.00
Current ratio 28.70 3.40 4.97
Net debt to EBITDA 4.65 0.00 1.01

Dividend

Metric GHRS URGN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric GHRS URGN Biotechnology median
Market cap 1.27b 1.26b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack